Website profile

Korea Biomedical Review

KBR

  • 170articles · 30d
  • 12+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 78%with images
  • 327avg words
articles per day
Categories
  • Medical 137
  • Health & Wellness 115
  • Health 92
  • Economy, Business & Finance 46
  • Science & Technology 22
  • Business & Industrial 19
  • Finance & Business 14
  • News 13

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


koreabiomed.com > news > articleView.html

Huinno passes technology assessment for Kosdaq special listing

15+ hour, 56+ min ago   (330+ words) Huinno, a digital healthcare company specializing in AI-powered cardiac monitoring, has passed the technology assessment required for a technology-based special listing on Kosdaq, moving a step closer to an initial public offering. Intermittent arrhythmias can be difficult to detect through…...


koreabiomed.com > news > articleView.html

China overtakes US in cancer research output, raising questions over Korea’s R&D system

3+ day, 15+ hour ago   (726+ words) China’s rapid rise in cancer research, fueled by heavy state investment, is challenging Korea to rethink a system that has long depended heavily on individual researchers, Korean cancer experts said Thursday. The warning comes as AI and big data increasingly…...


koreabiomed.com > news > articleView.html

Samsung Biologics discloses $261 mil. contract manufacturing agreement

4+ day, 9+ hour ago   (226+ words) Korea Biomedical Review Samsung Biologics said Thursday it had signed a 350.8 billion won ($261 million) contract to manufacture a biologic drug for an unnamed European pharmaceutical company, running through 2033. The Korean contract drug manufacturer disclosed the deal in a regulatory filing,…...


koreabiomed.com > news > articleView.html

Dong-A Socio Holdings to rename itself Dong-A Pharmaceutical after OTC merger

4+ day, 9+ hour ago   (274+ words) Dong-A Socio Holdings, the holding company behind one of Korea's oldest drugmakers, plans to rename itself Dong-A Pharmaceutical and directly operate its consumer healthcare business after absorbing its over-the-counter (OTC) subsidiary. Shareholders will vote Sept. 22 on a charter change that…...


koreabiomed.com > news > articleView.html

COSMECCA KOREA plans $150 mil. AI-based skincare factory in Korea

4+ day, 11+ hour ago   (192+ words) Korean cosmetics contract manufacturer COSMECCA KOREA said on Thursday it will invest 200 billion won ($150 million) to build a new skincare production complex, betting on sustained global demand for Korean beauty (K-beauty) products. The company, which makes cosmetics on an original…...


koreabiomed.com > news > articleView.html

Celltrion targets wider European growth for Omlyclo after gains in Spain, Italy

4+ day, 11+ hour ago   (440+ words) Celltrion is stepping up efforts to expand sales of its omalizumab biosimilar Omlyclo across Europe, building on an estimated market share exceeding 90 percent in Spain and sales above its business target in Italy, the company said Thursday. Omlyclo, used to…...


koreabiomed.com > news > articleView.html

Amorepacific's Ryo names actress Gong Seung-yeon global ambassador

4+ day, 15+ hour ago   (187+ words) Amorepacific’s scalp and hair-loss care brand Ryo has named actress Gong Seung-yeon as its new global ambassador alongside the launch of a revamped version of Root, its hair-loss care line targeting women. The company said it chose Gong because her…...


koreabiomed.com > news > articleView.html

Korea’s rare-disease drug market grows nearly fivefold in decade: IQVIA

4+ day, 13+ hour ago   (459+ words) Korea’s rare-disease drug market grew nearly fivefold over the past decade to about 1.2 trillion won ($896 million) in 2025, outpacing the broader pharmaceutical market, according to an IQVIA Korea analysis. IQVIA Korea said Thursday the findings were based on sales data from…...


koreabiomed.com > news > articleView.html

Yuyu Pharma CEO launches podcast on pet health, Korean culture

4+ day, 16+ hour ago   (198+ words) Korea Biomedical Review Yuyu Pharma CEO Robert Yu has launched “Robert’s YUniverse,” a podcast featuring conversations with guests on topics ranging from animal health research to Korean culture and global business. Yu, a third-generation member of the company’s founding family, hosts…...


koreabiomed.com > news > articleView.html

Korean surgeons operate on 99-year-old with torn aorta despite 30% survival odds

5+ day, 10+ hour ago   (356+ words) A 99-year-old man in Seoul has survived emergency heart surgery that his doctors thought he had little better than a one-in-three chance of surviving, after they concluded the alternative would kill him within a week. Lee Seung-man, a retired primary…...